SEC Form 4 · accession 0001628280-26-047909
Contineum Therapeutics, Inc. · CTNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel S. Lorrain
Officer — Chief Scientific Officer
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 5:20 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001855175
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jul 8, 2026 | M | 1,015 | $1.01 | A | 136,217 | D | |
| Class A Common Stock | Jul 8, 2026 | S | 1,015 | $16.00 | D | 135,202 | D | |
| Class A Common Stock | Jul 9, 2026 | M | 25 | $1.01 | A | 135,227 | D | |
| Class A Common Stock | Jul 9, 2026 | S | 25 | $16.00 | D | 135,202 | D | |
| Class A Common Stock | holding | — | — | — | 10,110 | I | By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.01 | Jul 8, 2026 | M | 1,015 | D | — | Feb 24, 2030 | Class A Common Stock | 1,015 | 33,282 | D |
| Stock Option (right to buy)F2 | $1.01 | Jul 9, 2026 | M | 25 | D | — | Feb 24, 2030 | Class A Common Stock | 25 | 33,257 | D |
Explanation of responses
- F1These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- F2The stock options are fully vested and exercisable.